Peapod Lane Capital’s Pliant Therapeutics PLRX Stock Holding History

Peapod Lane Capital’s Portfolio PLRX Stock Details PLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.49M	Buy	1,309,013 +20,435	+2%	+$24.9K	1.01%	48
2026 Q1	$1.59M	Buy	1,288,578 +402,204	+45%	+$508K	1.3%	36
2025 Q4	$1.08M	Sell	886,374 -210,654	-19%	-$316K	0.92%	43
2025 Q3	$1.62M	Buy	1,097,028 +203,298	+23%	+$310K	1.45%	30
2025 Q2	$1.04M	Buy	893,730 +251,537	+39%	+$355K	1.04%	41
2025 Q1	$867K	Buy	+642,193	New	+$3.9M	0.98%	38

Other funds holding PLRX

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

MAM

Monaco Asset Management Monaco $1.26B AUM 60.23% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

Peapod Lane Capital's PLRX Position: Q2 2026 in Review

Peapod Lane Capital increased its Pliant Therapeutics (PLRX) stake by 1.6% in Q2 2026, buying an estimated $24.9K and bringing the position to 1,309,013 shares worth $1.49M. The position accounts for 1.01% of the portfolio, ranked #48.

Peapod Lane Capital first reported a position in PLRX in Q1 2025 and has held it in 6 quarters since. The position peaked at $1.62M in Q3 2025. 86 funds tracked by Wall St. Rank hold PLRX as of Q2 2026.

Peapod Lane Capital held 1,309,013 shares of Pliant Therapeutics worth $1.49M as of Q2 2026.
Peapod Lane Capital bought 20,435 Pliant Therapeutics shares in Q2 2026, an estimated $24.9K.
Pliant Therapeutics made up 1.01% of Peapod Lane Capital's portfolio in Q2 2026, its #48 holding.
Peapod Lane Capital first reported a position in Pliant Therapeutics in Q1 2025 and has held it in 6 quarters since.
Peapod Lane Capital's Pliant Therapeutics position peaked at $1.62M in Q3 2025.
86 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q2 2026.

Based on Peapod Lane Capital's 13F filing for Q2 2026, filed 27 Jul 2026.